{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:49:24Z","timestamp":1792324164215,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jchromb.2025.124800","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:54:42Z","timestamp":1759301682000},"page":"124800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Characteristic analysis of adverse reactions to natural and synthetic alpha-glucosidase inhibitors: a descriptive analysis using World Health Organisation-VigiAccess"],"prefix":"10.1016","volume":"1267","author":[{"given":"Chunhui","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2025.124800_bb0005","unstructured":"Magliano DJ, Boyko EJ; IDF diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021. PMID: 35914061."},{"issue":"3","key":"10.1016\/j.jchromb.2025.124800_bb0010","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1039\/C9RA08706K","article-title":"SGLT inhibitors as antidiabetic agents: a comprehensive review","volume":"10","author":"Kshirsagar","year":"2020","journal-title":"RSC Adv."},{"issue":"23","key":"10.1016\/j.jchromb.2025.124800_bb0015","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.2174\/1381612825666190717104547","article-title":"Recent developments in alpha-glucosidase inhibitors for Management of Type-2 diabetes: An update","volume":"25","author":"Usman","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"25","key":"10.1016\/j.jchromb.2025.124800_bb0020","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.2174\/1568026622666220831092855","article-title":"Recent advances of \u03b1-glucosidase inhibitors: a comprehensive review","volume":"22","author":"Agrawal","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124800_bb0025","doi-asserted-by":"crossref","unstructured":"Development of Alpha-Glucosidase and Alpha-Amylase Inhibitors in Type 2 Diabetes Management: Insights from In silico to In vitro Studies. Curr Drug Targets. 2024 Aug 8. doi: https:\/\/doi.org\/10.2174\/0113894501313365240722100902. Epub ahead of print. PMID: 39129156.","DOI":"10.2174\/0113894501313365240722100902"},{"key":"10.1016\/j.jchromb.2025.124800_bb0030","doi-asserted-by":"crossref","unstructured":"Kaur N, Kumar V, Nayak SK, Wadhwa P, Kaur P, Sahu SK. Alpha-amylase as molecular target for treatment of diabetes mellitus: a comprehensive review. Chem. Biol. Drug Des. 2021 98(4):539\u2013560. doi: https:\/\/doi.org\/10.1111\/cbdd.13909. Epub 2021 Jul 4. PMID: 34173346.","DOI":"10.1111\/cbdd.13909"},{"issue":"6","key":"10.1016\/j.jchromb.2025.124800_bb0035","doi-asserted-by":"crossref","first-page":"817","DOI":"10.2337\/diacare.18.6.817","article-title":"Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM. A placebo-controlled dose-comparison study","volume":"18","author":"Coniff","year":"1995","journal-title":"Diabetes Care."},{"key":"10.1016\/j.jchromb.2025.124800_bb0040","doi-asserted-by":"crossref","unstructured":"Hossain U, Das AK, Ghosh S, Sil PC. An overview on the role of bioactive \u03b1-glucosidase inhibitors in ameliorating diabetic complications. Food Chem Toxicol. 2020 Nov;145:111738. doi: https:\/\/doi.org\/10.1016\/j.fct.2020.111738. Epub 2020 Sep 9. PMID: 32916220; PMCID: PMC7480666.","DOI":"10.1016\/j.fct.2020.111738"},{"key":"10.1016\/j.jchromb.2025.124800_bb0045","doi-asserted-by":"crossref","unstructured":"Ghani U. Re-exploring promising \u03b1-glucosidase inhibitors for potential development into oral anti-diabetic drugs: finding needle in the haystack. Eur. J. Med. Chem. 2015 Oct 20;103:133\u201362. doi: https:\/\/doi.org\/10.1016\/j.ejmech.2015.08.043. Epub 2015 Aug 28. PMID: 26344912.","DOI":"10.1016\/j.ejmech.2015.08.043"},{"issue":"4","key":"10.1016\/j.jchromb.2025.124800_bb0050","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.foodchem.2009.01.042","article-title":"Composition and enzyme inhibitory properties of finger millet (Eleusine coracana L.) seed coat phenolics: mode of inhibition of \u03b1-glucosidase and pancreatic amylase","volume":"115","author":"Shobana","year":"2009","journal-title":"Food Chem."},{"key":"10.1016\/j.jchromb.2025.124800_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115119","article-title":"Synthetic \u03b1-glucosidase inhibitors as promising anti-diabetic agents: recent developments and future challenges","volume":"249","author":"Mushtaq","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jchromb.2025.124800_bb0060","doi-asserted-by":"crossref","unstructured":"Lu QQ, Chen YM, Liu HR, Yan JY, Cui PW, Zhang QF, Gao XH, Feng X, Liu YZ. Nitrogen-containing flavonoid and their analogs with diverse B-ring in acetylcholinesterase and butyrylcholinesterase inhibition. Drug Dev. Res. 2020 81(8):1037\u20131047. doi: https:\/\/doi.org\/10.1002\/ddr.21726. Epub 2020 Aug 4. PMID: 32754990.","DOI":"10.1002\/ddr.21726"},{"issue":"02","key":"10.1016\/j.jchromb.2025.124800_bb0065","first-page":"221","article-title":"Study on the application of Sangzhi total alkaloids tablets combined with dapagliflozin in T2DM patients with HbA1c \u2265 9%","volume":"37","author":"Wang","year":"2024","journal-title":"J. Med. Theor. Pract."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124800_bb0070","first-page":"418","article-title":"Clinical observation on mulberry twig alkaloids tablets combined with insulin degludec and insulin aspart in treatment of type 2 diabetes mellitus","volume":"39","author":"Liu","year":"2024","journal-title":"Drugs & Clinic."},{"issue":"11","key":"10.1016\/j.jchromb.2025.124800_bb0075","first-page":"2208","article-title":"Comparison of clinical efficacy of Sangzhi alkaloids and Acarbose in patients with postprandial hyperglycemia caused by phlegm turbidity and blood stasis obstruction syndrome","volume":"35","author":"Fang","year":"2023","journal-title":"Clinical Journal of Traditional Chinese Medicine."},{"key":"10.1016\/j.jchromb.2025.124800_bb0080","unstructured":"Chinese Diabetes Society. Guideline for the prevention and treatment of diabetes mellitus in China (2024 edition).Chin J Diabetes Mellitus, 2025\uff0c17(01):16\u2013139. DOI:https:\/\/doi.org\/10.3760\/cma.j.cn115791-20241203-00705."},{"key":"10.1016\/j.jchromb.2025.124800_bb0085","doi-asserted-by":"crossref","unstructured":"Cortez-Navarrete M, P\u00e9rez-Rubio KG, Escobedo-Guti\u00e9rrez MJ. Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in type 2 diabetes mellitus treatment: a review. Pharmaceuticals (Basel) 2023;16(4):515. Published 2023 Mar 30. doi:https:\/\/doi.org\/10.3390\/ph16040515.","DOI":"10.3390\/ph16040515"},{"issue":"4","key":"10.1016\/j.jchromb.2025.124800_bb0090","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11101-021-09773-1","article-title":"A review of alpha-glucosidase inhibitors from plants as potential candidates for the treatment of type-2 diabetes","volume":"21","author":"Dirir","year":"2022","journal-title":"Phytochem. Rev."},{"key":"10.1016\/j.jchromb.2025.124800_bb0095","unstructured":"WHO. 2024. 2 Draft traditional medicine strategy: 2025 2034. https:\/\/cdn.who.int\/media\/docs\/default-source\/tci\/draft-traditional-medicine-strategy-2025-2034.pdf?sfvrsn=dd350962_1."},{"issue":"4","key":"10.1016\/j.jchromb.2025.124800_bb0100","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","article-title":"Investigating overlap in signals from EVDAS, FAERS, and VigiBase\u00ae","volume":"43","author":"Vogel","year":"2020","journal-title":"Drug Saf."},{"key":"10.1016\/j.jchromb.2025.124800_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1485067","article-title":"Characteristics of adverse reactions of three anti-glioma drugs in WHO-VigiAccess","volume":"15","author":"Ke","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124800_bb0110","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1470148","article-title":"DNA methylation inhibitors adverse reaction characteristic analysis: a descriptive analysis from WHO-VigiAccess","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124800_bb0115","doi-asserted-by":"crossref","unstructured":"Park G, Jung H, Heo SJ, Jung I. Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in Postmarketing surveillance. Life (Basel). 2020;10(8):138. Published 2020 Aug 5. doi:https:\/\/doi.org\/10.3390\/life10080138.","DOI":"10.3390\/life10080138"},{"key":"10.1016\/j.jchromb.2025.124800_bb0120","doi-asserted-by":"crossref","unstructured":"Hatamfayazi M, Mahdavi M, Moradi Dehaghi S, Khoshneviszadeh M, Iraji A. Synthesis and biological assessment of benzimidazole-acrylonitrile-1,2,3-triazole derivatives as \u03b1-glucosidase inhibitors. Bioorg. Chem. 2025 154:108060. doi: https:\/\/doi.org\/10.1016\/j.bioorg.2024.108060. Epub 2024 Dec 14. PMID: 39719821.","DOI":"10.1016\/j.bioorg.2024.108060"},{"key":"10.1016\/j.jchromb.2025.124800_bb0125","unstructured":"Liu Y, Wang R, Xia X, Shen Z, Xie M, Jin D, Jin Y, Zhu X, Liu Z, Jiang L. Review of the research and development of Ramulus Mori (Sangzhi) alkaloids (I) : technical barriers and large-scale development challenges in pharmaceutical research. Chinese Journal of Diabetes 2020;28 (7):555\u2013560. DOI: https:\/\/doi.org\/10.3969\/j.issn.1006-6187.2020.07.015."},{"key":"10.1016\/j.jchromb.2025.124800_bb0130","doi-asserted-by":"crossref","unstructured":"Wehmeier UF, Piepersberg W. Biotechnology and molecular biology of the alpha-glucosidase inhibitor acarbose. Appl. Microbiol. Biotechnol. 2004 63(6):613\u201325. doi: https:\/\/doi.org\/10.1007\/s00253-003-1477-2. Epub 2003 Dec 11. PMID: 14669056.","DOI":"10.1007\/s00253-003-1477-2"},{"issue":"3","key":"10.1016\/j.jchromb.2025.124800_bb0135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0026-0495(85)90010-1","article-title":"Alpha-glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus","volume":"34","author":"Dimitriadis","year":"1985","journal-title":"Metabolism"},{"issue":"9","key":"10.1016\/j.jchromb.2025.124800_bb0140","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/S0271-5317(05)80396-3","article-title":"Inhibition of intestinal \u03b1-glucosidase activity and postprandial hyperglycemia by \u03b1-glucosidase inhibitors in fa\/fa rats","volume":"11","author":"Madar","year":"1991","journal-title":"Nutr. Res."},{"key":"10.1016\/j.jchromb.2025.124800_bb0145","doi-asserted-by":"crossref","unstructured":"Patil P, Mandal S, Tomar SK, Anand S. Food protein-derived bioactive peptides in management of type 2 diabetes. Eur. J. Nutr. 2015 54(6):863\u201380. doi: https:\/\/doi.org\/10.1007\/s00394-015-0974-2. Epub 2015 Jul 8. PMID: 26154777.","DOI":"10.1007\/s00394-015-0974-2"},{"key":"10.1016\/j.jchromb.2025.124800_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.fitote.2023.105444","article-title":"Ramulus Mori (Sangzhi) alkaloids tablets for diabetes mellitus: a regulatory perspective","volume":"166","author":"An","year":"2023","journal-title":"Fitoterapia"},{"key":"10.1016\/j.jchromb.2025.124800_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fphar.2020.00315","article-title":"Intravitreal anti-VEGF drugs and signals of dementia and Parkinson-like events: analysis of the VigiBase database of spontaneous reports","volume":"11","author":"Sultana","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jchromb.2025.124800_bb0160","unstructured":"FDA. 2021. Best Practices for Conducting and Reporting Pharmacovigilance Analyses. https:\/\/www.fda.gov\/files\/drugs\/published\/Best-Practices-for-Conducting-and-Reporting-Pharmacoepidemiologic-Safety-Studies-Using-Electronic-Healthcare-Data-Sets.pdf."},{"key":"10.1016\/j.jchromb.2025.124800_bb0165","unstructured":"EMA. 2017. Reflection Paper on the Use of MedDRA in Pharmacovigilance. https:\/\/www.meddra.org\/how-to-use\/case-studies\/regulatory-case-study."},{"key":"10.1016\/j.jchromb.2025.124800_bb0170","article-title":"Real-world pharmacovigilance reports of hepatitis a inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system","volume":"15","author":"Zhou","year":"2025","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.jchromb.2025.124800_bb0175","unstructured":"ICH. 2020. E2B(R3) Electronic Transmission of Individual Case Safety Reports.https:\/\/collections.nlm.nih.gov\/catalog\/nlm:nlmuid-9918469488506676-pdf."},{"key":"10.1016\/j.jchromb.2025.124800_bb0180","doi-asserted-by":"crossref","unstructured":"Wang Z, Sheng J, Zhang X. Characterization of adverse reactions to four common targeted drugs for hepatocellular carcinoma in WHO-VigiAccess. Sci. Rep. 2025;15(1):16188. Published 2025 May 9. doi:https:\/\/doi.org\/10.1038\/s41598-025-00004-7.","DOI":"10.1038\/s41598-025-00004-7"},{"key":"10.1016\/j.jchromb.2025.124800_bb0185","unstructured":"FDA. 2020. CBER Biologics Effectiveness and Safety (BEST) System. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/cber-biologics-effectiveness-and-safety-best-system."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124800_bb0190","doi-asserted-by":"crossref","first-page":"242","DOI":"10.3390\/vaccines8020242","article-title":"Safety surveillance of pneumococcal vaccine using three algorithms: disproportionality methods, empirical Bayes geometric mean, and tree-based scan statistic","volume":"8","author":"Lee","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jchromb.2025.124800_bb0195","doi-asserted-by":"crossref","unstructured":"DuMouchel,William.Bayesian data mining in large frequency tables.Am. Stat., 1999, 53(3):177.DOI:https:\/\/doi.org\/10.1080\/00031305.1999.10474456.","DOI":"10.1080\/00031305.1999.10474456"},{"key":"10.1016\/j.jchromb.2025.124800_bb0200","doi-asserted-by":"crossref","unstructured":"Li M, Zhang QS, Liu XL, Wang HL, Liu W. Adverse Events Associated with Nirmatrelvir\/Ritonavir: A Pharmacovigilance Analysis Based on FAERS. Pharmaceuticals (Basel). 2022;15(12):1455. Published 2022 Nov 24. doi:https:\/\/doi.org\/10.3390\/ph15121455.","DOI":"10.3390\/ph15121455"},{"key":"10.1016\/j.jchromb.2025.124800_bb0205","doi-asserted-by":"crossref","unstructured":"Wang J, Wang CL, Guo L, Zhao SC, Wang DD, Zhang SQ., \"MDKAT: Multimodal Decoupling with Knowledge Aggregation and Transfer for Video Emotion Recognition,\" in IEEE Transactions on Circuits and Systems for Video Technology, doi: https:\/\/doi.org\/10.1109\/TCSVT.2025.3571534.","DOI":"10.1109\/TCSVT.2025.3571534"},{"issue":"10","key":"10.1016\/j.jchromb.2025.124800_bb0210","first-page":"75","article-title":"Pharmacodynamic study of three synthetic \u03b1 - glucosidase inhibitors for the treatment of diabetes","volume":"39","author":"Guo","year":"2009","journal-title":"Qinghai Med. J."},{"key":"10.1016\/j.jchromb.2025.124800_bb0215","unstructured":"Su Q. Adverse drug reactions of \u03b1-glucosidase inhibitors combined with other drugs Drug Eval. 2018;15(23):3\u20138 + 45. DOI: https:\/\/doi.org\/10.3969\/j.issn.1672-2809.2018.23.001."},{"key":"10.1016\/j.jchromb.2025.124800_bb0220","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/srep01377","article-title":"1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice","volume":"3","author":"Li","year":"2013","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jchromb.2025.124800_bb0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/dta.2992","article-title":"\u03b22 -adrenoceptor agonist activity of higenamine","volume":"13","author":"Hudzik","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jchromb.2025.124800_bb0230","doi-asserted-by":"crossref","unstructured":"Wang L, Li X, Men X, Liu X, Luo J. Research progress on antioxidants and protein aggregation inhibitors in cataract prevention and therapy (review). Mol. Med. Rep. 2025 31(1):22. doi: https:\/\/doi.org\/10.3892\/mmr.2024.13387. (Epub 2024 Nov 8. PMID: 39513587; PMCID: PMC11574704).","DOI":"10.3892\/mmr.2024.13387"},{"issue":"4","key":"10.1016\/j.jchromb.2025.124800_bb0235","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s11030-018-9839-y","article-title":"Structure-activity relationship investigation of coumarin-chalcone hybrids with diverse side-chains as acetylcholinesterase and butyrylcholinesterase inhibitors","volume":"22","author":"Kang","year":"2018","journal-title":"Mol. Divers."},{"key":"10.1016\/j.jchromb.2025.124800_bb0240","doi-asserted-by":"crossref","unstructured":"Gao XH, Tang JJ, Liu HR, Liu LB, Liu YZ. Structure-activity study of fluorine or chlorine-substituted cinnamic acid derivatives with tertiary amine side chain in acetylcholinesterase and butyrylcholinesterase inhibition. Drug Dev. Res. 2019 80(4):438\u2013445. doi: https:\/\/doi.org\/10.1002\/ddr.21515. Epub 2019 Jan 24. PMID: 30680760.","DOI":"10.1002\/ddr.21515"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322500354X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S157002322500354X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T21:06:33Z","timestamp":1781211993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S157002322500354X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"alternative-id":["S157002322500354X"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124800","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Characteristic analysis of adverse reactions to natural and synthetic alpha-glucosidase inhibitors: a descriptive analysis using World Health Organisation-VigiAccess","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2025.124800","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"124800"}}